作者
Erin F Cobain, Yi-Mi Wu, Pankaj Vats, Rashmi Chugh, Francis Worden, David C Smith, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Megan EV Caram, Daniel F Hayes, Elena M Stoffel, Michelle F Jacobs, Chandan Kumar-Sinha, Xuhong Cao, Rui Wang, David Lucas, Yu Ning, Erica Rabban, Janice Bell, Sandra Camelo-Piragua, Aaron M Udager, Marcin Cieslik, Robert J Lonigro, Lakshmi P Kunju, Dan R Robinson, Moshe Talpaz, Arul M Chinnaiyan
发表日期
2021/4/1
期刊
JAMA oncology
卷号
7
期号
4
页码范围
525-533
出版商
American Medical Association
简介
Importance
Use of next-generation sequencing (NGS) to identify clinically actionable genomic targets has been incorporated into routine clinical practice in the management of advanced solid tumors; however, the clinical utility of this testing remains uncertain.
Objective
To determine which patients derived the greatest degree of clinical benefit from NGS profiling.
Design, Setting, and Participants
Patients in this cohort study underwent fresh tumor biopsy and blood sample collection for genomic profiling of paired tumor and normal DNA (whole-exome or targeted-exome capture with analysis of 1700 genes) and tumor transcriptome (RNA) sequencing. Somatic and germline genomic alterations were annotated and classified according to degree of clinical actionability. Results were returned to treating oncologists. Data were collected from May 1, 2011, to February 28, 2018, and analyzed from May 1, 2011, to April 30 …
学术搜索中的文章
EF Cobain, YM Wu, P Vats, R Chugh, F Worden… - JAMA oncology, 2021